Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Aurelie Najm AurelieRheumo
3 years 1 month ago
Multiplex peripheral blood in 200+ ILD pts
Differences in IL-17 RD-ILD>IPF> IPAF
Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF
OR 0.4
Almost surprising considering known profibrotic role of IL-13 🧐
https://t.co/21UMq6w9hI
Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO
TheDaoIndex KDAO2011
3 years 1 month ago
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
Julian Segan JulianSegan
3 years 1 month ago
Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy.
@RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR
Richard Conway RichardPAConway
3 years 1 month ago
Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
#ACR22 Advancing Telemedicine in Rheumatology
'60% prefer telemedicine for routine visits and review lab results'
https://t.co/HUgoocXodE
@RheumNow #ACR22
Dr. Rachel Tate uptoTate
3 years 1 month ago
Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh
Olga Petryna DrPetryna
3 years 1 month ago
#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5
David Liew drdavidliew
3 years 1 month ago
There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID
sheila RHEUMarampa
3 years 1 month ago
Did you know?
Teratogens may take the form of:
✳️Drugs & chemicals
✳️Physical agents
✳️Infections
✳️Metabolic conditions
#ACR22 @Rheumnow #MedTwitter https://t.co/GfHL28RYjm
David Liew drdavidliew
3 years 1 month ago
USA vs Canada
It's kicking off
and a super hot topic
The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis
Holers/Deane (treat 🇺🇸)
El Gabalawy/Pope (don't treat 🇨🇦)
What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf
Richard Conway RichardPAConway
3 years 1 month ago
Terrier @TerrierBen et al Mepolizumab in vasculitic type EGPA in MIRRA. Vasculitic features similar in patients who did/did not achieve remission. Decreased flares of all type, including vasculitic. @RheumNow #ACR22 Abstr#1075 https://t.co/0MkJvnCnf1 https://t.co/ZxbDqlvgae
Dr. Rachel Tate uptoTate
3 years 1 month ago
Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ
Richard Conway RichardPAConway
3 years 1 month ago
Bekker et al. Safety of avacopan across 3 trials. Rates of AEs, SAEs, infection all lower in avacopan group. @RheumNow #ACR22 Abstr#1077 https://t.co/n4zhC2zf8k https://t.co/Q8raSEERah
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr# Interesting data for IMID patients who had #COVID. A cohort study in Norway (1/3 had RA and mostly on TNFi; 6% RTX) showed greater anti-Spike Ab in 4th vaccine vs 3rd dose. However, the greatest was in those with 3 x doses + COVID infection (Hybrid) @RheumNow https://t.co/hGFSGqJtBT
Poster Hall